NCT04298229View on ClinicalTrials.gov

Efficacy and Safety of Dapagliflozin in Acute Heart Failure

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

April 1, 2020

Primary Completion Date

May 17, 2023

Study Completion Date

May 17, 2023

Conditions
Heart FailureDiabetes Mellitus, Type 2
Interventions
DRUG

Dapagliflozin 10 MG

SGLT2 inhibitors being investigated for its diuretic and natriuretic effects on top of protocolized diuretic therapy.

OTHER

Protocolized Diuretic Therapy

Structured usual care arm with protocolized diuretic therapy based on urine output.

Trial Locations (6)

27514

University of North Carolina, Chapel Hill

37203

TriStar Centennial Medical Center, Nashville

37205

Saint Thomas West Hospital, Nashville

37232

Vanderbilt University Medical Center, Nashville

39216

University of Mississippi Medical Center, Jackson

73112

INTEGRIS, Oklahoma City

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Vanderbilt University Medical Center

OTHER